Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.62 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.62 |
| ▸ | TTR | P02766 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 6/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 6/20 | 0.56 |
| ▸ | ALOX15B | O15296 | 3/20 | 0.54 |
| ▸ | RARA | P10276 | 1/20 | 0.45 |
| ▸ | RARB | P10826 | 1/20 | 0.45 |
| ▸ | RARG | P13631 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17565590 | 0.91 | ESR2 (0.78) | ESR1ESR2TTRALOX15ALOX12 | |
| SCHEMBL19861143 | 0.88 | ESR2 (0.83) | ESR1ESR2TTRALOX15ALOX12 | |
| SCHEMBL17679253 | 0.88 | ESR2 (0.83) | ESR1ESR2TTRALOX15ALOX12 | |
| SCHEMBL31545730 | 0.88 | ESR2 (0.83) | ESR1ESR2TTRALOX15ALOX12 | |
| SCHEMBL29525502 | 0.83 | ALOX12 (0.78) | ESR1ESR2TTRALOX15ALOX12 | |
| SCHEMBL10559567 | 0.83 | ALOX12 (0.78) | ESR1ESR2TTRALOX15ALOX12 | |
| Aus-131 SCHEMBL29005752 | 0.80 | ESR2 (0.79) | ESR1ESR2TTRALOX15ALOX12 | |
| Aus-131 SCHEMBL29005768 | 0.80 | ESR2 (0.79) | ESR1ESR2TTRALOX15ALOX12 | |
| Aus-131 SCHEMBL29005767 | 0.80 | ESR2 (0.79) | ESR1ESR2TTRALOX15ALOX12 | |
| SCHEMBL12433393 | 0.77 | ALOX15B (0.43) | ESR1ESR2TTRALOX15ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716497-B2 | Method for enantioselective hydrogenation of chromenes | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2014-05-06 | — | — | US | disclosed |
| US-20130116450-A1 | METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES | GIRINDUS AMERICA, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-8263790-B2 | Method for enantioselective hydrogenation of chromenes | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2012-09-11 | — | — | US | disclosed |
| US-20120004427-A1 | METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES | GIRINDUS AMERICA, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-7960573-B2 | Method for enantioselective hydrogenation of chromenes | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2011-06-14 | — | — | US | disclosed |
| US-20100069653-A1 | METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES | Children hospital medical center (US) | 2010-03-18 | — | — | US | disclosed |
| US-7528267-B2 | Method for enantioselective hydrogenation of chromenes | GIRINDUS AMERICA, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20080108696-A1 | Phytoestrogenic Formulations for Alleviation or Prevention of Neurodegenerative Diseases | UNIVERSITY OF SOUTHERN CALIFORNIA | 2008-05-08 | — | — | US | disclosed |
| US-20070027329-A1 | Method for enantioselective hydrogenation of chromenes | AUSIO PHARMACEUTICALS, LLC | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116450-A1 | METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES | HRH3, HRH2, CHD8 | ESR1 11/4885ESR2 7/4885TTR 4208/4885 |
| US-20070027329-A1 | Method for enantioselective hydrogenation of chromenes | HRH3, HRH2, CHD8 | ESR1 11/4885ESR2 7/4885TTR 4208/4885 |
| US-20080108696-A1 | Phytoestrogenic Formulations for Alleviation or Prevention of Neurodegenerative Diseases | ESR1, ESR2, SHBG | ESR1 1/4885ESR2 2/4885TTR 485/4885 |
| US-20120004427-A1 | METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES | HRH3, HRH2, CHD8 | ESR1 11/4885ESR2 7/4885TTR 4208/4885 |
| US-20100069653-A1 | METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES | HRH3, HRH2, CHD8 | ESR1 11/4885ESR2 7/4885TTR 4208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.